Pembrolizumab, (anti-PD-1 antibody) is used for first-line treatment in ALK and EGFR wild-type advanced NSCLC that have a high (≥50%) PD-L1 expression on tumour cells as determined by immunohistochemistry (IHC) [4]. Here, EGFR is linked to non-small cell lung carcinoma.